Corixa Corp.’s stock took a dive Wednesday after the FDA said in a “complete review letter” that the company failed to provide sufficient evidence of safety and clinical benefit in its biologics license application for the non-Hodgkin’s lymphoma drug Bexxar. (BioWorld Today)
Corixa Corp.’s stock took a dive Wednesday after the FDA said in a “complete review letter” that the company failed to provide sufficient evidence of safety and clinical benefit in its biologics license application for the non-Hodgkin’s lymphoma drug Bexxar. (BioWorld Today)
Myriad Genetics Inc. entered a deal worth upward of $34 million with Abbott Laboratories Inc. to identify genes and drug targets for the diagnosis and treatment of depression. (BioWorld Today)
Myriad Genetics Inc. entered a deal worth upward of $34 million with Abbott Laboratories Inc. to identify genes and drug targets for the diagnosis and treatment of depression. (BioWorld Today)
SIGA Technologies Inc. and Allergy Therapeutics Holdings Ltd. agreed to a stock-for-stock merger that will combine research and development strengths of each company to lead to quicker advances in drug development. (BioWorld Today)
SIGA Technologies Inc. and Allergy Therapeutics Holdings Ltd. agreed to a stock-for-stock merger that will combine research and development strengths of each company to lead to quicker advances in drug development. (BioWorld Today)
